New Corona Medication Guideline Created by the Society for the first time September 9 0:00
As research on new coronavirus treatment progresses, the Japan Society of Intensive Care Medicine and others have analyzed papers from around the world, and for the first time have created guidelines that summarize which treatments can be recommended according to the patient's condition.
Research on the treatment of the new coronavirus is progressing, but the mechanism of the disease is not fully understood, and various therapeutic agents are used according to the symptoms of the patient.
Against this backdrop, the Japan Society of Intensive Care Medicine and the Japan Emergency Medicine Society have, for the first time, created guidelines that summarize what drugs should be administered to patients in any condition, after analyzing research papers from countries around the world.
It is strongly recommended that the steroid "Dexamethasone" should be given to moderate and severe patients, but not to mild patients.
In addition, remdecibir, which was first approved in Japan as a novel viral treatment, has not been confirmed to be effective in mildly ill patients and is not recommended at this time, but it is weakly administered to moderately or severely ill patients. I recommend it.
Furthermore, “Abigan”, which is developed by a Japanese pharmaceutical company and is undergoing clinical research, is weakly recommended for mild patients and is not currently recommended for moderate or severe patients.
The guidelines will be published on the websites of the two academic societies, and we will scrutinize and update the content of new papers as they become available.
Nishida Repair Director, Japan Society of Intensive Care Medicine, said, “We have arranged various information regarding treatments so that they can be useful in the field. The new coronavirus needs to be treated as soon as possible, so please refer to it. I want to do it."